Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy

Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy

ABSTRACT SARS-CoV-2 variants of concern (VOC) acquired mutations in the spike (S) protein, including E484K, that confer resistance to neutralizing antibodies. However, it is incompletely understood how these mutations impact viral entry into host cells. Here, we analyzed how mutations at position 48...

Full description

Bibliographic Details
Main Authors: Markus Hoffmann, Anzhalika Sidarovich, Prerna Arora, Nadine Krüger, Inga Nehlmeier, Amy Kempf, Luise Graichen, Martin S. Winkler, Daniela Niemeyer, Christine Goffinet, Christian Drosten, Sebastian Schulz, Hans-Martin Jäck, Stefan Pöhlmann
Format: Article
Language:English
Published: American Society for Microbiology 2022-06-01
Series:mBio
Subjects:
ACE2
COVID-19
antibody
neutralization
spike
Online Access:https://journals.asm.org/doi/10.1128/mbio.00364-22

Internet

https://journals.asm.org/doi/10.1128/mbio.00364-22

Similar Items